Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

246 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07335380 2026-01-29

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

Phase 1 Not yet recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02819752 2026-01-21

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

128 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07168785 2025-09-11

[18F]-AraG PET Imaging in LA HNSCC

Phase EARLY_PHASE1 Not yet recruiting

5 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03070366 2025-09-02

OMET

Phase 2 Active not recruiting

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04091867 2025-02-24

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Phase 1 Completed

3 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04857164 2025-01-28

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Phase 2 Recruiting

150 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06714266 2024-12-03

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04747054 2024-10-26

PembroMetaRT

Phase 3 Recruiting

102 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Neoplasm Metastasis

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05992610 2023-08-15

iCHRTL

Phase NA Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

NCT04572100 2023-07-07

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

Phase 1 Completed

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT02158234 2023-01-19

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Phase 1 Completed

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Diseases

NCT05136768 2021-11-29

LM-HNSCC

Phase 2 Unknown

50 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT02052960 2021-11-02

RESGEX

Phase 2 Completed

240 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03673735 2021-05-10

ADHERE

Phase 3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Phase 2 Recruiting

53 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04220749 2020-09-04

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Phase 2 Recruiting

68 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00002654 2019-05-15

Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer

Phase 3 Completed

224 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Phase 1 Completed

15 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT01425736 2014-06-03

Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

91 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00002496 2014-01-24

Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx

Phase 3 Completed

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00002670 2014-01-24

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

Phase 3 Completed

459 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00095641 2013-11-08

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

PEACH

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

[18F]-AraG PET Imaging in LA HNSCC

OMET

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PembroMetaRT

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

iCHRTL

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

QUASAR

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

LM-HNSCC

RESGEX

ADHERE

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma

Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer